Top

Published in:

Open Access 01-12-2009 | Original Paper

Nuclear Localization of CXCR4 Determines Prognosis for Colorectal Cancer Patients

Authors: Frank M. Speetjens, Gerrit Jan Liefers, Cornelis J. Korbee, Wilma E. Mesker, Cornelis J.H. van de Velde, Ronald L. van Vlierberghe, Hans Morreau, Rob A. Tollenaar, Peter J.K. Kuppen

Published in: Cancer Microenvironment | Issue 1/2009

Abstract

Chemokines and their receptors are implicated in formation of colorectal cancer metastases. Especially CXCR4 is an important factor, determining migration, invasiveness, metastasis and proliferation of colorectal cancer cells. Object of this study was to determine expression of CXCR4 in tumor tissue of colorectal cancer patients and associate CXCR4 expression levels to clinicopathological parameters. Levels of CXCR4 expression of a random cohort of patients, who underwent primary curative resection of a colorectal carcinoma, were retrospectively determined by quantitative real-time RT-PCR and semi-quantitative analyses of immunohistochemical stained paraffin sections. Expression levels were associated to clinicopathological parameters. Using RT-PCR we found that a high expression of CXCR4 in the primary tumor was an independent prognostic factor for a poor disease free survival (p = 0.03, HR: 2.0, CI = 1.1–3.7). Immunohistochemical staining showed that nuclear distribution of CXCR4 in the tumor cells was inversely associated with disease free and overall survival (p = 0.04, HR: 2.6, CI = 1.0–6.2), while expression in the cytoplasm was not associated with prognosis. In conclusion, our study showed that a high expression of nuclear localized CXCR4 in tumor cells is an independent predictor for poor survival for colorectal cancer patients.

Paget S (1889) The distribution of secondary growths in cancer of the breast. Lancet 1:571–573CrossRef

Fuchs E (1882) Das Sarkom des Uvealtractus. Graefe’s Archiv für Ophthalmologie XII:233

Ruffini PA, Morandi P, Cabioglu N et al (2007) Manipulating the chemokine-chemokine receptor network to treat cancer. Cancer 109:2392–2404CrossRefPubMed

Zlotnik A, Yoshie O, Nomiyama H (2006) The chemokine and chemokine receptor superfamilies and their molecular evolution. Genome Biol 7:243CrossRefPubMed

Bacon K, Baggiolini M, Broxmeyer H et al (2002) Chemokine/chemokine receptor nomenclature. J Interferon Cytokine Res 22:1067–1068CrossRefPubMed

Muller A, Homey B, Soto H et al (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410:50–56CrossRefPubMed

Zeelenberg IS, Ruuls-Van Stalle L, Roos E (2003) The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases. Cancer Res 63:3833–3839PubMed

Koshiba T, Hosotani R, Miyamoto Y et al (2000) Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression. Clin Cancer Res 6:3530–3535PubMed

Taichman RS, Cooper C, Keller ET et al (2002) Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 62:1832–1837PubMed

10.

Kim J, Mori T, Chen SL et al (2006) Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome. Ann Surg 244:113–120CrossRefPubMed

11.

Lapteva N, Yang AG, Sanders DE et al (2005) CXCR4 knockdown by small interfering RNA abrogates breast tumor growth in vivo. Cancer Gene Ther 12:84–89CrossRefPubMed

12.

Liang Z, Yoon Y, Votaw J et al (2005) Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res 65:967–971PubMed

13.

Ottaiano A, Franco R, Aiello TA et al (2006) Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II–III colorectal cancer patients. Clin Cancer Res 12:2795–2803CrossRefPubMed

14.

Kim J, Takeuchi H, Lam ST et al (2005) Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol 23:2744–2753CrossRefPubMed

15.

Schimanski CC, Schwald S, Simiantonaki N et al (2005) Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer. Clin Cancer Res 11:1743–1750CrossRefPubMed

16.

Ottaiano A, di Palma A, Napolitano M et al (2005) Inhibitory effects of anti-CXCR4 antibodies on human colon cancer cells. Cancer Immunol Immunother 54:781–791CrossRefPubMed

17.

Jordan NJ, Kolios G, Abbot SE et al (1999) Expression of functional CXCR4 chemokine receptors on human colonic epithelial cells. J Clin Invest 104:1061–1069CrossRefPubMed

18.

Dwinell MB, Eckmann L, Leopard JD et al (1999) Chemokine receptor expression by human intestinal epithelial cells. Gastroenterology 117:359–367CrossRefPubMed

19.

Rollins BJ (1997) Chemokines. Blood 90:909–928PubMed

20.

Salvucci O, Bouchard A, Baccarelli A et al (2006) The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study. Breast Cancer Res Treat 97:275–283CrossRefPubMed

21.

Wang N, Wu QL, Fang Y et al (2005) Expression of chemokine receptor CXCR4 in nasopharyngeal carcinoma: pattern of expression and correlation with clinical outcome. J Transl Med 3:26CrossRefPubMed

22.

Spano JP, Andre F, Morat L et al (2004) Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: pattern of expression and correlation with outcome. Ann Oncol 15:613–617CrossRefPubMed

23.

Woo SU, Bae JW, Kim CH, et al (2007) A significant correlation between nuclear CXCR4 expression and axillary lymph node metastasis in hormonal receptor negative breast cancer. Ann Surg Oncol

24.

Dierssen JW, de Miranda NF, Ferrone S et al (2007) HNPCC versus sporadic microsatellite-unstable colon cancers follow different routes toward loss of HLA class I expression. BMC Cancer 7:33CrossRefPubMed

25.

Speetjens FM, de Bruin EC, Morreau H et al (2008) Clinical impact of HLA class I expression in rectal cancer. Cancer Immunol Immunother 57:601–609CrossRefPubMed

26.

de Jong AE, van PM, Hendriks Y et al (2004) Microsatellite instability, immunohistochemistry, and additional PMS2 staining in suspected hereditary nonpolyposis colorectal cancer. Clin Cancer Res 10:972–980CrossRefPubMed

27.

Balkwill F (2004) The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol 14:171–179CrossRefPubMed

28.

Contento RL, Molon B, Boularan C et al (2008) CXCR4-CCR5: a couple modulating T cell functions. Proc Natl Acad Sci U S A 105:10101–10106CrossRefPubMed

29.

Wald O, Izhar U, Amir G et al (2006) CD4+CXCR4highCD69+ T cells accumulate in lung adenocarcinoma. J Immunol 177:6983–6990PubMed

30.

Shim H, Lau SK, Devi S et al (2006) Lower expression of CXCR4 in lymph node metastases than in primary breast cancers: potential regulation by ligand-dependent degradation and HIF-1alpha. Biochem Biophys Res Commun 346:252–258CrossRefPubMed

31.

Lin SY, Makino K, Xia W et al (2001) Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol 3:802–808CrossRefPubMed

32.

Huang YC, Hsiao YC, Chen YJ, et al (2007) Stromal cell-derived factor-1 enhances motility and integrin up-regulation through CXCR4, ERK and NF-kappaB-dependent pathway in human lung cancer cells. Biochem Pharmacol

Title: Nuclear Localization of CXCR4 Determines Prognosis for Colorectal Cancer Patients
Authors: Frank M. Speetjens
Gerrit Jan Liefers
Cornelis J. Korbee
Wilma E. Mesker
Cornelis J.H. van de Velde
Ronald L. van Vlierberghe
Hans Morreau
Rob A. Tollenaar
Peter J.K. Kuppen
Publication date: 01-12-2009
Publisher: Springer Netherlands
Published in: Cancer Microenvironment / Issue 1/2009
Print ISSN: 1875-2292
Electronic ISSN: 1875-2284
DOI: https://doi.org/10.1007/s12307-008-0016-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2009

Dual FGF-2 and Intergrin α5β1 Signaling Mediate GRAF-Induced RhoA Inactivation in a Model of Breast Cancer Dormancy

Stromal Myofibroblasts Accompany Modifications in the Epithelial Phenotype of Tongue Dysplastic and Malignant Lesions

Regulated Expression of CCL21 in the Prostate Tumor Microenvironment Inhibits Tumor Growth and Metastasis in an Orthotopic Model of Prostate Cancer

Genotype-Dependent Tumor Regression in Marek’s Disease Mediated at the Level of Tumor Immunity

The NF-κB/AKT-dependent Induction of Wnt Signaling in Colon Cancer Cells by Macrophages and IL-1β

Identification of Molecular Distinctions Between Normal Breast-Associated Fibroblasts and Breast Cancer-Associated Fibroblasts

Keynote webinar | Spotlight on antibody–drug conjugates in cancer